AP2014007400A0 - 4-Piperidinyl compounds for use as tankyrase inhibitors - Google Patents

4-Piperidinyl compounds for use as tankyrase inhibitors

Info

Publication number
AP2014007400A0
AP2014007400A0 AP2014007400A AP2014007400A AP2014007400A0 AP 2014007400 A0 AP2014007400 A0 AP 2014007400A0 AP 2014007400 A AP2014007400 A AP 2014007400A AP 2014007400 A AP2014007400 A AP 2014007400A AP 2014007400 A0 AP2014007400 A0 AP 2014007400A0
Authority
AP
ARIPO
Prior art keywords
piperidinyl compounds
tankyrase inhibitors
tankyrase
inhibitors
piperidinyl
Prior art date
Application number
AP2014007400A
Other languages
English (en)
Inventor
Christine Hiu-Tung Chen
Lucian V Dipietro
Jianme Fan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AP2014007400A0 publication Critical patent/AP2014007400A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AP2014007400A 2011-07-13 2012-07-13 4-Piperidinyl compounds for use as tankyrase inhibitors AP2014007400A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161507321P 2011-07-13 2011-07-13
PCT/IB2012/053613 WO2013008217A1 (en) 2011-07-13 2012-07-13 4 - piperidinyl compounds for use as tankyrase inhibitors

Publications (1)

Publication Number Publication Date
AP2014007400A0 true AP2014007400A0 (en) 2014-01-31

Family

ID=46604017

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007400A AP2014007400A0 (en) 2011-07-13 2012-07-13 4-Piperidinyl compounds for use as tankyrase inhibitors

Country Status (21)

Country Link
US (2) USRE46942E1 (OSRAM)
EP (1) EP2731940B1 (OSRAM)
JP (1) JP5957077B2 (OSRAM)
KR (1) KR20140051944A (OSRAM)
CN (1) CN103797006B (OSRAM)
AP (1) AP2014007400A0 (OSRAM)
AU (1) AU2012282076A1 (OSRAM)
BR (1) BR112014000792A2 (OSRAM)
CA (1) CA2841932A1 (OSRAM)
CO (1) CO6880065A2 (OSRAM)
CR (1) CR20140071A (OSRAM)
DO (1) DOP2014000012A (OSRAM)
EA (1) EA201490272A1 (OSRAM)
ES (1) ES2548513T3 (OSRAM)
IL (1) IL230430A0 (OSRAM)
MA (1) MA35342B1 (OSRAM)
MX (1) MX2014000536A (OSRAM)
PH (1) PH12014500126A1 (OSRAM)
TN (1) TN2014000016A1 (OSRAM)
WO (1) WO2013008217A1 (OSRAM)
ZA (1) ZA201400374B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520858A (ja) * 2011-07-13 2014-08-25 ノバルティス アーゲー タンキラーゼ阻害剤として用いるための新規な2−ピペリジン−1−イル−アセトアミド化合物
DK2822656T3 (en) 2012-03-07 2017-01-30 Inst Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
MX364438B (es) * 2013-03-15 2019-04-26 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
AU2014304953B2 (en) * 2013-08-07 2018-02-22 Merck Patent Gmbh Piperidine urea derivatives
WO2015036759A1 (en) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
WO2015135461A1 (zh) * 2014-03-10 2015-09-17 四川海思科制药有限公司 取代的二氢苯并呋喃-哌啶-甲酮衍生物、其制备及用途
EP3140295B1 (en) 2014-05-07 2018-09-12 Merck Patent GmbH Heterocyclyl-butanamide derivatives
KR101739003B1 (ko) 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
WO2016006974A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
BR112018007358A2 (pt) * 2015-11-02 2018-10-23 Merck Patent Gmbh derivados de 1,4-dicarbonil-piperidila
KR101777475B1 (ko) 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
CN109311868B (zh) 2015-12-22 2022-04-01 尚医治疗有限责任公司 用于治疗癌症和炎性疾病的化合物
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
IL271230B2 (en) 2017-06-21 2024-06-01 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020114892A1 (en) 2018-12-03 2020-06-11 Merck Patent Gmbh 4-heteroarylcarbonyl-n-(phenyl or heteroaryl) piperidine-1-carboxamides as inhibitors of tankyrases
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
KR20220047810A (ko) * 2019-08-15 2022-04-19 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 알키닐 퀴나졸린 화합물
US20240041859A1 (en) * 2020-12-03 2024-02-08 Washington University Methods of treating and preventing kidney disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
EP1142881A4 (en) 1999-01-14 2003-05-07 Meiji Seika Kaisha POLY (ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10056312A1 (de) 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
US20050107404A1 (en) 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
DE10201240A1 (de) 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
AU2003211381B9 (en) 2002-02-19 2009-07-30 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
US7439254B2 (en) 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
GB0405101D0 (en) * 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
ATE540936T1 (de) 2004-06-30 2012-01-15 Janssen Pharmaceutica Nv Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
EP1789390B1 (en) 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP2008546843A (ja) 2005-06-27 2008-12-25 アムゲン インコーポレイティッド 抗炎症性アリールニトリル化合物
AU2007244904B2 (en) * 2006-04-25 2012-05-31 Eli Lilly And Company Inhibitors of 11-Beta-hydroxysteroid dehydrogenase 1
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
JP5658565B2 (ja) 2007-09-12 2015-01-28 ジェネンテック, インコーポレイテッド ホスホイノシチド3−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
WO2009059994A2 (en) 2007-11-05 2009-05-14 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
KR101179753B1 (ko) 2007-11-06 2012-09-04 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
RU2490260C2 (ru) 2008-03-27 2013-08-20 Янссен Фармацевтика Нв Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина
JP2014520858A (ja) * 2011-07-13 2014-08-25 ノバルティス アーゲー タンキラーゼ阻害剤として用いるための新規な2−ピペリジン−1−イル−アセトアミド化合物

Also Published As

Publication number Publication date
ES2548513T3 (es) 2015-10-19
US9163003B2 (en) 2015-10-20
MA35342B1 (fr) 2014-08-01
USRE46942E1 (en) 2018-07-10
BR112014000792A2 (pt) 2017-10-31
JP5957077B2 (ja) 2016-07-27
WO2013008217A1 (en) 2013-01-17
PH12014500126A1 (en) 2014-02-24
DOP2014000012A (es) 2014-07-31
KR20140051944A (ko) 2014-05-02
NZ620426A (en) 2015-08-28
CO6880065A2 (es) 2014-02-28
EP2731940B1 (en) 2015-08-19
IL230430A0 (en) 2014-03-31
CA2841932A1 (en) 2013-01-17
CN103797006A (zh) 2014-05-14
ZA201400374B (en) 2014-10-29
CR20140071A (es) 2014-10-16
JP2014522855A (ja) 2014-09-08
AU2012282076A1 (en) 2014-02-27
CN103797006B (zh) 2016-01-27
EA201490272A1 (ru) 2014-05-30
EP2731940A1 (en) 2014-05-21
MX2014000536A (es) 2014-12-05
US20150126513A1 (en) 2015-05-07
TN2014000016A1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
IL273079B (en) Heterocycloamines as pi3k inhibitors
ZA201400374B (en) 4-piperidinyl compounds for use as tankyrase inhibitors
ZA201400232B (en) Metalloenzyme inhibitor compounds
ZA201305612B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
EP2723730A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
IL228103A0 (en) Amino-quinolines as kinase inhibitors
ZA201306997B (en) Triazolopyridine compounds as pim kinase inhibitors
HUE037899T2 (hu) Metalloenzim inhibitor vegyületek
IL231403A0 (en) Thiazolopyridine compounds as a10pde inhibitors
EP2751117A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
HK1195060A (en) 4 - piperidinyl compounds for use as tankyrase inhibitors